Xellia Pharmaceuticals Aps

Hikma has set out expected enhancements to its injectables business, following the completion of its recent agreement to acquire a bundle of US finished-dose assets from Xellia Pharmaceuticals foll

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

COVID-19 has exposed many weaknesses in pandemic preparedness, not least when it comes to active pharmaceutical ingredients, and Carl-Åke Carlsson CEO of API and FDF manufacturer Xellia Pharmaceutica

When top corporate officials began cold-calling federal agencies during the March 2020 pandemic lockdown to see how Eastman Kodak Co. , which manufactures chemicals, could help reduce expected shorta